Selected Publications

Jung IY, Bartoszek RL, Rech AJ, Collins SM, Ooi SK, Williams EF, Hopkins CR, Narayan V, Haas NB, Frey NV, Hexner EO, Siegel DL, Plesa G, Porter DL, Cantu A, Everett JK, Guedan S, Berger SL, Bushman FD, Herbst F, Fraietta JA. Type I Interferon Signaling via the EGR2 Transcriptional Regulator Potentiates CAR T cell-intrinsic Dysfunction.
Cancer Discov. 2023 Apr 3:CD-22-1175
 

Dimitri A, Herbst F, Fraietta JA.
Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing.
Mol Cancer, 2022 Mar 18;21(1):78
 

Dieter SM, Siegl C, Codo P, Huerta M, Ostermann-Parucha A, Schulz E, Zowada MK, Martin S, Laaber K, Nowrouzi A, Blatter M, Kreth S, Westermann F, Benner A, Uhrig U, Putzker K, Lewis J, Haegebarth A, Mumberg D, Holton, SJ, Weiske J, Toepper LM, Scheib U, Siemeister G, Ball CR, Kuster B, Stoehr G, Hahne H, Johannes S, Lange M, Herbst F, Glimm H.
Degradation of Cyclin K/CDK12 is a druggable vulnerability of colorectal cancer.                      
Cell Reports, 2021 Jul 20;36(3):109394
 

Herbst F, Lang T, Eckert ESP, Wünsche P, Kindinger T, Laaber K, Hemmati S, Hotz-Wagenblatt A, Zavidij O, Paruzynski A, Lu J, von Kalle C, Zenz T, Klein C, Schmidt M, Ball CR, Glimm H.
The balance between the intronic miR-342 and its host gene Evl determines hematopoietic cell fate decision.         
Leukemia, 2021 Oct;35(10):2948-2963
 

Hanf D, Heining C, Laaber K, Nebelung H, Uhrig S, Hutter B, Jahn A, Richter D, Aust D, Herbst F, Fröhling S*, Glimm H*, Folprecht G*.
Response to cabozantinib following acquired entrectinib resistance in a patient with ETV6-NTRK3 fusion-positive carcinoma harboring the NTRK3G623R solvent-front mutation.
JCO Precis Oncol, 2021 Apr 22;5: PO.20.00278
 

Wünsche P, Eckert ESP, Holland-Letz T, Paruzynski A, Hotz-Wagenblatt A, Fronza R, Rath T, Gil-Farina I, Schmidt M, von Kalle C, Klein C, Ball CR, Herbst F*, Glimm H*.
Mapping active gene-regulatory regions in human repopulating long-term HSCs.
Cell Stem Cell, 2018 Jul 5;23(1):132-146